Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.

Annals of surgical oncology - 1 Dec 2013

Yoo Seol Bong, Kim Yu Jung, Kim Hyojin, Jin Yan, Sun Ping-Li, Jheon Sanghoon, Lee Jong Seok, Chung Jin-Haeng

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) mutation alone may be insufficient to predict clinical outcomes in the response to EGFR-tyrosine kinase inhibitor (TKI) therapy. The secondary mutation T790 M and MET amplification are mechanisms of acquired resistance to EGFR-TKI in approximate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Cadherins
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-met

Share to PTEN Phosphohydrolase

Share to Tissue Array Analysis

Source

Identifiers

PMID: 23579873
DOI: 10.1245/s10434-013-2970-1

Genes

EGFR
MET
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23579873-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.PMID 23579873Read ↗

β-Catenin Contributes to Lung Tumor Development Induced by EGFR MutationsSemantic proximity Read ↗

Deranged expression of the E‐cadherin/β‐catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomasSemantic proximity Read ↗

Cadherin and catenin alterations in human cancer.Semantic proximity Read ↗

Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.Semantic proximity Read ↗

Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance.Semantic proximity Read ↗

The Expression Pattern of p120-Catenin is Associated With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.Semantic proximity Read ↗

Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas.Semantic proximity Read ↗

E-cadherin-catenin cell-cell adhesion complex and human cancer.Semantic proximity Read ↗

Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer.Semantic proximity Read ↗

The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study.Semantic proximity Read ↗

Erbb Receptors and Epithelial-Cadherin–Catenin Complex In Human CarcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.